LABORATOIRES EUROMEDIS (ALEMG.PA) Fundamental Analysis & Valuation

EPA:ALEMG • FR0000075343

Current stock price

4.68 EUR
-0.02 (-0.43%)
Last:

This ALEMG.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ALEMG.PA Profitability Analysis

1.1 Basic Checks

  • In the past year ALEMG has reported negative net income.
  • The reported net income has been mixed in the past 5 years: ALEMG reported negative net income in multiple years.
  • In multiple years ALEMG reported negative operating cash flow during the last 5 years.
ALEMG.PA Yearly Net Income VS EBIT VS OCF VS FCFALEMG.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -13.77%, ALEMG is doing worse than 72.58% of the companies in the same industry.
  • ALEMG has a Return On Equity of -33.03%. This is in the lower half of the industry: ALEMG underperforms 70.97% of its industry peers.
Industry RankSector Rank
ROA -13.77%
ROE -33.03%
ROIC N/A
ROA(3y)0.89%
ROA(5y)6.05%
ROE(3y)1.29%
ROE(5y)13.59%
ROIC(3y)N/A
ROIC(5y)N/A
ALEMG.PA Yearly ROA, ROE, ROICALEMG.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

  • ALEMG has a Gross Margin of 26.77%. This is amonst the worse of the industry: ALEMG underperforms 88.71% of its industry peers.
  • In the last couple of years the Gross Margin of ALEMG has remained more or less at the same level.
  • ALEMG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.6%
GM growth 5Y1.2%
ALEMG.PA Yearly Profit, Operating, Gross MarginsALEMG.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ALEMG.PA Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ALEMG remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, ALEMG has less shares outstanding
  • The debt/assets ratio for ALEMG has been reduced compared to a year ago.
ALEMG.PA Yearly Shares OutstandingALEMG.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
ALEMG.PA Yearly Total Debt VS Total AssetsALEMG.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • ALEMG has an Altman-Z score of 1.89. This is not the best score and indicates that ALEMG is in the grey zone with still only limited risk for bankruptcy at the moment.
  • ALEMG has a worse Altman-Z score (1.89) than 61.29% of its industry peers.
  • ALEMG has a Debt/Equity ratio of 0.52. This is a neutral value indicating ALEMG is somewhat dependend on debt financing.
  • ALEMG has a Debt to Equity ratio (0.52) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z 1.89
ROIC/WACCN/A
WACCN/A
ALEMG.PA Yearly LT Debt VS Equity VS FCFALEMG.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

  • ALEMG has a Current Ratio of 3.07. This indicates that ALEMG is financially healthy and has no problem in meeting its short term obligations.
  • ALEMG has a Current ratio of 3.07. This is amongst the best in the industry. ALEMG outperforms 82.26% of its industry peers.
  • A Quick Ratio of 2.25 indicates that ALEMG has no problem at all paying its short term obligations.
  • The Quick ratio of ALEMG (2.25) is better than 83.87% of its industry peers.
Industry RankSector Rank
Current Ratio 3.07
Quick Ratio 2.25
ALEMG.PA Yearly Current Assets VS Current LiabilitesALEMG.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ALEMG.PA Growth Analysis

3.1 Past

  • The earnings per share for ALEMG have decreased strongly by -144.11% in the last year.
  • The Revenue for ALEMG has decreased by -26.59% in the past year. This is quite bad
  • ALEMG shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -14.02% yearly.
EPS 1Y (TTM)-144.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.64%
Revenue 1Y (TTM)-26.59%
Revenue growth 3Y-31.34%
Revenue growth 5Y-14.02%
Sales Q2Q%11.95%

3.2 Future

  • Based on estimates for the next years, ALEMG will show a small growth in Earnings Per Share. The EPS will grow by 7.07% on average per year.
  • ALEMG is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -18.80% yearly.
EPS Next Y8.35%
EPS Next 2Y7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year7.54%
Revenue Next 2Y-18.8%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ALEMG.PA Yearly Revenue VS EstimatesALEMG.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
ALEMG.PA Yearly EPS VS EstimatesALEMG.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

3

4. ALEMG.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • ALEMG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 9.91, which indicates a very decent valuation of ALEMG.
  • Based on the Price/Forward Earnings ratio, ALEMG is valued cheaply inside the industry as 90.32% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of ALEMG to the average of the S&P500 Index (22.67), we can say ALEMG is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.91
ALEMG.PA Price Earnings VS Forward Price EarningsALEMG.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALEMG.PA Per share dataALEMG.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.07%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALEMG.PA Dividend Analysis

5.1 Amount

  • ALEMG does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALEMG.PA Fundamentals: All Metrics, Ratios and Statistics

LABORATOIRES EUROMEDIS

EPA:ALEMG (3/24/2026, 7:00:00 PM)

4.68

-0.02 (-0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-27
Earnings (Next)04-23
Inst Owners2.03%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap13.43M
Revenue(TTM)38.40M
Net Income(TTM)-5.48M
Analysts37.14
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.91
P/S 0.35
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 0.81
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)0.47
Fwd EY10.09%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS13.38
BVpS5.78
TBVpS5.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.77%
ROE -33.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 26.77%
FCFM N/A
ROA(3y)0.89%
ROA(5y)6.05%
ROE(3y)1.29%
ROE(5y)13.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.6%
GM growth 5Y1.2%
F-ScoreN/A
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.07
Quick Ratio 2.25
Altman-Z 1.89
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-144.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.64%
EPS Next Y8.35%
EPS Next 2Y7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.59%
Revenue growth 3Y-31.34%
Revenue growth 5Y-14.02%
Sales Q2Q%11.95%
Revenue Next Year7.54%
Revenue Next 2Y-18.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y68.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

LABORATOIRES EUROMEDIS / ALEMG.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALEMG.PA.


Can you provide the valuation status for LABORATOIRES EUROMEDIS?

ChartMill assigns a valuation rating of 3 / 10 to LABORATOIRES EUROMEDIS (ALEMG.PA). This can be considered as Overvalued.


What is the profitability of ALEMG stock?

LABORATOIRES EUROMEDIS (ALEMG.PA) has a profitability rating of 1 / 10.


How financially healthy is LABORATOIRES EUROMEDIS?

The financial health rating of LABORATOIRES EUROMEDIS (ALEMG.PA) is 5 / 10.


How sustainable is the dividend of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?

The dividend rating of LABORATOIRES EUROMEDIS (ALEMG.PA) is 0 / 10 and the dividend payout ratio is 0%.